Abbott's Multi-Cylinder Growth Engine Outperforms S&P 500 Expectations
Abbott Laboratories (ABT) hissedarı, şirketin sağlık sektöründeki endişeleri aşıp +10.7% artışla piyasa açılışını gerçekleştirdi. Bu, S&P 500'ün geril
Abbott Laboratories (ABT) shares surged +10.7% at market open, outperforming the S&P 500's decline. The company's quarterly earnings of $1.31 beat estimates of $1.28 and lifted full-year profit guidance to $5.45-$5.60.
Beyond Libre: A Diversified Growth Story
Abbott's growth narrative shifted beyond its Libre CGM system. While Diabetes Care sales topped $2 billion but slowed to 9.5% growth, Diagnostics surged 13% and Medical Devices gained traction with new electrophysiology products.
Data Debunks Healthcare Slowdown Fears
Market concerns over declining hospital procedures were dismissed by Abbott's real-time diagnostic data, which showed stable demand. CEO noted 'strong and stable testing demand,' reinforcing confidence in the healthcare sector.
Ege Kaan (Wall Street Strategist): Abbott's diversification mitigates sector risks while rewriting market expectations. This could reshape S&P 500 growth narratives.
Related News & Analysis
View All →
Singh Joins Mayfield: A New Era for Chip Investments
Ramp Unveils Model Router, Steering the AI Landscape into a New Era
WNBA’s Landmark Pay Raise: 364% Surge in Player Wages Sparks Labor Milestone
Gen Z Rewrites the American Dream in the Great Postponement
Inertia Enterprises Cuts Fusion Fuel Loading to Hours, Shaking the Energy Market
Patreon Unveils 30 New Features to Revolutionize Creator Ecosystem
Latest Market News
All News →Rising Yields Threaten to Burst the Stock-Market Bubble: How Markets Will React
Human Capital Resilience in the Age of AI: Implications for Financial Markets
![[ALKLC] ALTINKILIÇ GIDA VE SÜT SANAYİ TİCARET A.Ş.
Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu](/_next/image?url=%2Fuploads%2Fkap-default.png&w=3840&q=75)
[ALKLC] ALTINKILIÇ GIDA VE SÜT SANAYİ TİCARET A.Ş. Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu
Turkey Cuts Inflation Target from 75–80% to 30%: Bolat’s Bold Move
Hyperliquid Goes to the US: Regulatory and Market Shockwaves